Nova Patents
WO0185196A3

Cxcr4 antagonist treatment of hematopoietic cells

Abstract

In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used therapeutically to stimulate hematopoietic stem/progenitor cell multiplication/self-renewal.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Published
  4. Today

Every citation, both waysCites: the store holds 3 of 4

Citations
DocumentRelationOfficeCategoryCited duringRelevant claims
WO0009152A1CitesWorld Intellectual Property Organization (WIPO)XInternational search1-4,6-13,21-30
WO0066112A1CitesWorld Intellectual Property Organization (WIPO)XPYInternational search1-3,6,7,21-30
WO9804698A1CitesWorld Intellectual Property Organization (WIPO)YInternational search1-13,21-30
PELED A. ET AL.: "Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4.", SCIENCE, vol. 283, 1999, pages 845 - 848, XP002180064Non-patent––International search–
AIUTI A. ET AL.: "SDF-1 is a chemoattractant for human CD34+ progenitor cells and provides a new mechanism to explain their mobilization to peropheral blood.", BLOOD, vol. 88, no. 10 Suppl. 1, 1996, pages 455A, XP001021112Non-patent––International search–
CRUMP M P ET AL: "SOLUTION STRUCTURE AND BASIS FOR FUNCTIONAL ACTIVITY OF STROMAL CELL-DERIVED FACTOR-18: DISSOCIATION OF CXCR4 ACTIVATION FROM BINDING AND INHIBITION OF HIV-1", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 16, no. 23, 1997, pages 6996 - 7007, XP002915918, ISSN: 0261-4189Non-patent––International search–